Brought to you by 
Relypsa brings in $70mm through its Series B venture round
24 Sep 2010
Executive Summary
Relypsa Inc. (developing nonabsorbed polymeric therapeutics for cardiovascular and renal conditions) has raised $70mm through the closing of its Series B venture round. New investor OrbiMed Advisors led the financing (and contributes a board member) and was joined by current shareholders New Leaf Venture Partners, 5AM Ventures, Delphi Ventures, Sprout Group, and Mediphase Venture Partners. The company will use the funds to continue working on RLY5016, which has finished Phase II for chronic and acute hyperkalemia, a disease prevalent in patients with renal impairment, hypertension, diabetes, and heart failure.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Relypsa brings in $70mm through its Series B venture round
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice